The overall purpose of the trial is to assess the clinical efficacy of three different subcutaneous doses of BI 655066 in adult patients with AS, in order to provide clinical proof of concept and to select dose (s) for confirmatory clinical trials.

Read more: http://www.clinicaltrials.gov/ct2/show/NCT02047110?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30